Quest Diagnostics (DGX) SVP Mark Delaney Sells 1,600 Shares

What Happened
Mark E. Delaney, SVP and Chief Commercial Officer of Quest Diagnostics (DGX), sold 1,600 shares on July 28, 2026. The shares were disposed at $235.18 per share for total proceeds of $376,288. This was a sale (not a purchase) and was reported on Form 4 the next day.

Key Details

• Transaction date: 2026-07-28; reported filed: 2026-07-29 (appears timely).
• Price: $235.18 per share; Shares sold: 1,600; Total proceeds: $376,288.
• Transaction type: Sale (open market/private sale designation on the Form 4).
• Footnote: Sale effected pursuant to a Rule 10b5-1 sales plan (prearranged trading plan).
• Shares owned after transaction: Not specified in the provided filing details.

Context
A sale under a Rule 10b5-1 plan is typically prearranged and does not necessarily reflect the insider’s current view of the company. Sales are common among executives for diversification or liquidity; purchases generally provide stronger signals of insider confidence. This filing shows a routine, planned sale rather than an opportunistic market-timed trade.